Swine are an important host in influenza virus ecology since they are susceptible to infections with both avian and human influenza A viruses.

​This Expert Opinion outlines some pre-conditions that are considered to be essential at the national level prior to the use of new drugs for the treatment of tuberculosis, as well as specific conditions needed in order to successfully implement new TB drugs/regimens.

This guidance report lays down the scientific basis for the potential introduction of human papillomavirus (HPV) vaccines in order to help EU Member States to make policy choices

This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.

A consultation with European and international public health experts was convened to review data presented in newly conducted systematic reviews and meta-analyses regarding influenza antivirals, in order to develop an ECDC Expert Opinion.

Current childhood vaccination schedules are the result of historical tradition, compliance with provision of health services and national vaccine registration. They have been designed on the basis of different needs related to how the healthcare system – but also the education system – is organised at national level.

The final expert opinion on rotavirus vaccination in infancy aims to provide EU/EEA Member States with information to support the decision-making process on the possible introduction of rotavirus vaccination in infancy.

This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.

ECDC has published an Expert Opinion on rotavirus vaccination in infancy. The paper provides EU/EEA Member States with relevant scientific information on burden of rotavirus disease, vaccine effectiveness and safety, and cost-effectiveness studies to support the decision-making process on the possible introduction of routine vaccination of children against rotavirus gastroenteritis.

This expert opinion is intended to support national decision-making by summarising the considerations and concerns of some EU/EEA countries when they discussed whether to introduce the 4CMenB vaccine into their national immunisation programmes.